To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Inclusion criteria: * Histologically confirmed, solid tumor refractory to standard therapy. * Tumor for which there is no standard therapy. * Able to swallow and retain oral medication. * ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2. * Provided written informed consent. * Adequate bone marrow function. * Serum creatinine is less than or equal to 1.5 mg/dL. * Calculated creatinine clearance is greater than or equal to 60 ml/min based on Cockcroft and Gault. * Total bilirubin is greater than or equal to the upper limit of normal of institutional values. * Aspartate and alanine transaminase is less than or equal to 3 times the upper limit of the institutional values. * Have a left ventricular ejection fraction (LVEF) greater than or equal to 40% based on electrocardiogram (ECHO) or multiple gated acquisition scan (MUGA). * Resting oxygen saturations of greater than 90%. Exclusion criteria: * Pregnant or lactating female. * Have malabsorption syndrome, a disease affecting gastrointestinal function. * Resection of the stomach or small bowel. * Evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease. * Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations. * Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product. * Use of anilinoquinazolines, such as gefitinib \[Iressa™\], erlotinib \[Tarceva™\]. * Immediate or delayed hypersensitivity reaction to midazolam or any component of the formulation, including benzyl alcohol (cross-sensitivity with other benzodiazepines may exist). * Has narrow-angle glaucoma which is a contraindication to midazolam use. * Has received treatment with any investigational drug in the previous 4 weeks. * Received chemotherapy, immunotherapy, biologic therapy or hormonal therapy within the past 14 days, with the exception of mitomycin C within the past 6 weeks. * Currently receiving amiodarone or has received amiodarone in the 6 months prior to screening. * Is taking regular doses of opiates that in the opinion of the investigator would put the patient at risk of clinically significant respiratory compromise when midazolam is administered. * Physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. * Has Class II to IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. * Clinically significant electrocardiogram (ECG) abnormality. * Clinically assessed to have inadequate venous access for protocol-related blood draws.